Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2002
11/28/2002WO2002094795A1 4-aminopyrimidine derivatives
11/28/2002WO2002094794A1 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002WO2002094790A1 Fused heterocyclic compound and medicinal use thereof
11/28/2002WO2002094787A1 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
11/28/2002WO2002094786A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002WO2002094785A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002WO2002094784A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002WO2002094783A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002WO2002094782A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derativatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002WO2002094780A2 Kinases and phosphatases
11/28/2002WO2002094774A2 Oxcarbazepine dosage forms
11/28/2002WO2002094768A2 Aza hydroxylated ethyl amine compounds
11/28/2002WO2002094767A2 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002WO2002094754A1 Vitamin d analogues
11/28/2002WO2002094378A2 Increased functional activity and/or expression of abc transporters protects against the loss of dopamine neurons associated with parkinson's disease
11/28/2002WO2002094308A1 Improved neuronal gene transfer
11/28/2002WO2002094306A1 Remedies for nervous tumor
11/28/2002WO2002094305A1 Use of tripeptide gpe for treating or preventing symptoms of parkinson's disease
11/28/2002WO2002094297A1 Herbal composition for the treatment of drug addiction and insomnia
11/28/2002WO2002094272A1 Analgesic composition and method
11/28/2002WO2002094263A2 Caspase inhibitors and uses thereof
11/28/2002WO2002094262A1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors
11/28/2002WO2002094259A1 Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
11/28/2002WO2002094254A2 Abuse resistant pharmaceutical composition containing capsaicin
11/28/2002WO2002094249A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain
11/28/2002WO2002094236A1 Delivery of antipsychotics through an inhalation route
11/28/2002WO2002094225A1 Granular preparations of gaboxadol
11/28/2002WO2002094220A1 Liquid pharmaceutical composition
11/28/2002WO2002094218A2 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002WO2002094203A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002WO2002094202A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
11/28/2002WO2002094192A2 Antibodies against tumor necrosis factor delta (april)
11/28/2002WO2002094189A2 Compositions and methods for treating or preventing convulsions or seizures
11/28/2002WO2002094186A2 Urazole compounds useful as anti-inflammatory agents
11/28/2002WO2002094176A2 Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
11/28/2002WO2002085897A8 Heterocyclic compounds for aging-related and diabetic vascular complications
11/28/2002WO2002085896A8 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
11/28/2002WO2002083712A8 Transporters and ion channels
11/28/2002WO2002080887A3 Timed pulse release composition
11/28/2002WO2002078745A3 Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
11/28/2002WO2002078641A3 Pyrrolidine sulfonamides
11/28/2002WO2002078629A3 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
11/28/2002WO2002078616A3 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
11/28/2002WO2002076440A3 Methods of treating alzheimer's disease with piperidin derivates
11/28/2002WO2002072631A8 Mhc molecule constructs and their usesfor diagnosis and therapy
11/28/2002WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002WO2002070532A3 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
11/28/2002WO2002064557A9 New crystal forms of oxcarbazepine and processes for their preparation
11/28/2002WO2002047711A3 Modulators of activity of g-protein-coupled receptor kinases
11/28/2002WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002WO2002034920A3 Regulation of human ceruloplasmin-like protein
11/28/2002WO2002029049A3 Regulation of human sodium-dependent monoamine transporter
11/28/2002WO2002024924A3 Protein phosphatases
11/28/2002WO2002022665A9 Novel g protein-coupled receptor proteins and dnas tehreof
11/28/2002WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002WO2001098360A3 Gp354 nucleic acids and polypeptides
11/28/2002WO2001089497A3 Praziquantel compositions for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/28/2002WO2001035942A9 Analgesic compositions containing buprenorphine
11/28/2002WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002US20020178459 Genetically engineered mammal for use in the treatment of muscle and liver disorders
11/28/2002US20020177722 Method for the preparation of citalopram
11/28/2002US20020177626 Comprises analgesics such as ibuprofen and diphenhydramine; storage stability
11/28/2002US20020177622 Neuroprotectants; enhancing cognition
11/28/2002US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002US20020177617 Method of treating migraines and pharmaceutical compositions
11/28/2002US20020177616 Such as 2-(4-((((2R)-8-isopropoxy-chroman-2-yl)-methyl)amino) butyl)-1,2-benzisothiazol-3(2H)-one for prophylaxis and/or treatment of Parkinson's disease
11/28/2002US20020177614 Preventing neural tissue damage caused by adenosine-diphosphate- ribosylation of eucaryotic elongation factor-2 (EF-2)
11/28/2002US20020177609 Fatty alcohol drug conjugates
11/28/2002US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002US20020177596 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist
11/28/2002US20020177595 Novel compounds useful as neuro-protective agents
11/28/2002US20020177591 Central nervous system (CNS); diazabicyclo compounds such as 1,4-Diaza-bicyclo(3.2.2)nonane-4-carboxylic acid, 4-cyclohexyl-phenyl ester; CNS-penetrant alpha 7 nicotinic receptor agonist
11/28/2002US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002US20020177556 Especially treating Alzheimer's disease with cetrorelix.
11/28/2002US20020177213 Tissue plasminogen activator-like protease
11/28/2002US20020177187 Nucleotide sequences coding polypeptide for use in the treatment of nervous system disorders
11/28/2002US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002US20020176888 Oral dosage forms
11/28/2002US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002US20020176872 Pain treatment by peripheral administration of a neurotoxin
11/28/2002US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002DE10125763A1 New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
11/28/2002DE10125145A1 New C-furanyl- or C-thienyl-methylamine derivatives, useful e.g. for treating arrhythmia, emesis, inflammation, cardiovascular or neurodegenerative disease, asthma, glaucoma or especially pain
11/28/2002DE10123586A1 New 3,5-diamino-1,2,4-triazole derivatives, are cyclin dependent kinase inhibitors useful for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
11/28/2002DE10122140A1 Rekombinante Fusionsproteine und deren Trimere Recombinant fusion proteins and their trimers
11/28/2002CA2641760A1 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
11/28/2002CA2450535A1 Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
11/28/2002CA2448102A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof
11/28/2002CA2448084A1 Aza hydroxylated ethyl amine compounds
11/28/2002CA2448080A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/28/2002CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002CA2447671A1 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
11/28/2002CA2447603A1 Granular preparations of gaboxadol
11/28/2002CA2447598A1 Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
11/28/2002CA2447465A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain
11/28/2002CA2447340A1 Kinases and phosphatases
11/28/2002CA2447338A1 Receptors and membrane-associated proteins
11/28/2002CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002CA2446734A1 Antibodies against tumor necrosis factor delta (april)
1 ... 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 ... 1833